Clinical Course of Congenital Hypothyroidism With Gland In Situ and Necessity of L-Thyroxine Therapy After Re-evaluation.

CONTEXT

The clinical course and need for long-term L-thyroxine (LT4) therapy of congenital hypothyroidism (CH) with gland in situ (GIS) remain unclear.

OBJECTIVE

To describe the clinical history of CH with GIS and evaluate the proportion of patients who can suspend therapy during follow-up.

DESIGN AND SETTING

Retrospective evaluation of patients followed at referral regional center for CH of Pisa.

PATIENTS

Seventy-seven patients with confirmed primary CH and GIS after positive neonatal screening were included. All children started LT4 upon CH confirmation on serum assay.

INTERVENTIONS

At 3 years of age, 55 children underwent a clinical reevaluation after withdrawal of therapy with hormonal examinations, imaging of the thyroid gland with ultrasonography, and 123-iodine with perchlorate discharge test. Subsequent periodic controls of thyroid function were executed, and, when possible, a new attempt to stop LT4 was performed. Adequate follow-up data (at least 6 months after treatment suspension trial) were available for 49 patients.

RESULTS

Among the 55 patients who were reassessed, 18 (32.7%) were euthyroid. Considering subsequent follow-up, 49% of patients were no longer treated and 51% were taking therapy. No differences in neonatal parameters were observed between the 2 groups; LT4 dose before the last trial off medication was higher in permanent CH (P .016).

CONCLUSION

Monitoring thyroid function in children with CH and GIS is necessary to evaluate the need for substitution and avoid overtreatment. Even if therapy can be suspended, patients need to be monitored because apparently normal thyroid function may decline several months after withdrawal of LT4.

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected]. See the journal About page for additional terms.